Amphastar Pharmaceuticals heads into early summer with a badly damaged chart, a crowded short book, and a Street that has turned firmly against the name — all in the wake of a catastrophic Q1 print.
The short interest story is the defining dynamic right now. Bears have rebuilt aggressively since the May 7 earnings implosion, and short interest has climbed back toward cycle highs. At 11.4% of the free float — up roughly 9% week-on-week and materially above the ~10.5% level seen at the start of March — the short book is not reversing. FINRA's fortnightly official data corroborates the trend, showing 3.78 million shares short with 4.7 days-to-cover, giving any squeeze attempt a real time-cost. What's notable is the direction: shorts were actually trimming throughout late April and the first week of May, only to reload hard after the print. The mid-May low in short interest (~3.47 million shares) has already been eclipsed, and the rebuild has been steady every session since May 26.
The borrow market tells a looser story, but one worth watching. Availability is generous — roughly 331% of current short interest, meaning lenders hold more than three shares in reserve for every one already borrowed — so there is no mechanical squeeze pressure in the lending pool. Borrowing costs have also settled back toward 0.49%, down around 7% on the week and still technically low. Cost to borrow did spike sharply through mid-May, briefly touching 0.70%, which coincided with the post-earnings short rebuild. That it has since eased back suggests the borrow supply expanded to meet demand rather than tightened — shorts are finding shares without paying a premium. Options markets reinforce this lack of urgency: the put/call ratio is running at 0.054, barely above its 20-day average of 0.049 and a world away from the 52-week high of 0.62. Options traders are not hedging aggressively into whatever comes next.
The Street, however, has become decisively more cautious. Analysts have been cutting targets relentlessly since February, and the direction of travel has only accelerated post-earnings. This week, Barclays lowered its target to $20 from $23 while holding Equal-Weight. Wells Fargo downgraded to Equal-Weight from Overweight in mid-May, slashing its target from $30 to $19. Needham dropped to Hold from Buy. Jefferies moved the same way in late April, cutting to Hold with a $22 target versus a prior $30. Piper Sandler trimmed to $21. The mean target across the group is $22.83 — still roughly 24% above the current $18.45 close, but that gap reflects stale optimism from earlier in the year more than fresh conviction. Factor scores confirm the fundamental erosion: EPS momentum over 30 days ranks in the bottom 16th percentile of the universe, and 90-day momentum is barely better at the 27th. The stock has shed nearly 16% over the past month. The ORTEX short score of 62.6 has been climbing steadily from the mid-60s on May 20, signalling that the quantitative positioning signal has moved more firmly into bearish territory over the past two weeks.
The earnings history frames the current fragility starkly. The May 7 Q1 release produced a one-day drop of 20.5% and a five-day decline of 27.6% — one of the sharpest post-print collapses the stock has seen. The bears' bear case centres on pricing headwinds in iron sucrose and glucagon, competition eroding the generics franchise, and limited visibility on new product launches. Bulls point to Baqsimi's ongoing ramp and the Eli Lilly partnership as reasons for eventual recovery, and EV/EBITDA of 5.3x and a P/E of 6.4x look cheap in any absolute sense — the EV/EBIT factor ranks in the top 17% of the universe. But cheap multiples have not arrested the sell-off, and the bull case requires catalysts the stock has so far failed to deliver.
On the institutional side, the ownership structure shows a concentration that matters. Applied Physics & Chemistry Laboratories holds 15.5% of shares — a founder-adjacent strategic stake that has been unchanged for some time. CEO Jack Zhang controls a further 6.1% through his personal holding entity, and insiders across the table were sellers in March at prices around $18.10–$18.91 per share, very close to where the stock trades today. The March selling was small in absolute dollar terms — the CEO's combined transactions total well under $400,000 — but the direction is consistent with the broader tone. Marshall Wace trimmed 211,644 shares through end of March, while American Century was adding 352,202 shares in the same period, illustrating the divergence between the more sceptical and the more opportunistic holders. The ORTEX short score of 62.6 is near its highest reading of the recent period, and with peers like AMRX and PRGO also declining on the week by roughly 1% and 3% respectively, there is no sector tailwind offering cover.
The next scheduled earnings event is August 7. Between now and then, the key variables to watch are whether short interest continues to climb above 11.5% of free float, whether analysts resume cutting targets closer to the current price, and whether any pipeline or partnering news emerges to shift the narrative on Baqsimi growth.
See the live data behind this article on ORTEX.
Open AMPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
